Wladimir Hogenhuis
Patrimonio netto: 622 310 $ in data 30/06/2026
Patrimonio netto: 622 310 $ in data 30/06/2026
Wladimir Hogenhuis currently works at Driver Bioengineering, Inc., as President, Chief Executive Officer & Director from 2022, Rezolute, Inc., as Independent Director from 2021, GATT Technologies BV, as Director from 2020, and IHP Therapeutics, Inc., as Director.
Mr. Hogenhuis also formerly worked at Vision 2020, as Director, Merck & Co., Inc., as General Manager-Neuroscience, Ultragenyx Pharmaceutical, Inc., as Chief Operating Officer from 2018 to 2020, and GSK Plc, as Senior Vice President from 2012 to 2018.
Mr. Hogenhuis received his doctorate degree from the University of Leiden and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
REZOLUTE, INC. 0,14% | 16/12/2025 | 119.675 ( 0,14% ) | 622 310 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| REZOLUTE, INC. | Direttore/Membro del Consiglio | 02/03/2021 |
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Direttore/Membro del Consiglio | 01/05/2020 |
IHP Therapeutics, Inc. | Direttore/Membro del Consiglio | - |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor | Amministratore Delegato | 28/04/2022 |
| Società | Posizione | Fine |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Direttore operativo | 10/01/2020 |
| GSK PLC | Corporate Officer/Principal | 01/09/2018 |
Vision 2020 | Direttore/Membro del Consiglio | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Leiden
University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vision 2020 | |
Rezolute, Inc.
Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor | Health Technology |
IHP Therapeutics, Inc. |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale